Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04984538
Other study ID # PGX-INITIATIVE-TRHC-2020-002
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date July 1, 2021
Est. completion date January 30, 2023

Study information

Verified date January 2023
Source Tabula Rasa HealthCare
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations (described above). Presently, CareKinesis services more than 35 PACE organizations, including approximately 100 PACE sites, across the United States. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes. Pharmacist-led PGx clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by TRHC (CareKinesis). Our aim is to extend and meticulously study PGx testing for more PACE patients and conduct a prospective preemptive PGx study to determine feasibility of implementation and effect on outcomes. After mutual agreement, these services may also be extended to other organizations where TRHC provides pharmacy services, and data will be collected with patient consent.


Description:

This project aims to include patients enrolled in PACE organizations or other healthcare organizations serviced by TRHC. PGx testing will be performed by a vendor contracted by TRHC (CLIA certified). Genetic testing for CYP450 isoforms like CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A5, and transporters like SLCO1B1, ABCB1, and ABCG2 will be conducted, along with other genes in individual vendors' testing panel. The results will be integrated into TRHC's proprietary CDSS (Medication Risk Mitigation Matrix, Tabula Rasa Healthcare, Moorestown, NJ). Phenotypes related to CYP450 isoforms will be used to guide pharmacists to identify drug-drug interactions (DDIs), drug-gene interactions (DGIs), and drug-drug-gene interactions (DDGIs).(16) Clinical pharmacists will translate PGx results combined with a comprehensive DDI review into actionable clinical recommendations. Prescribers will review the pharmacist's recommendation, and based on their clinical assessment will decide whether or not to implement the therapy recommendation. Endpoints like number and type of pharmacist recommendations and uptake by physicians, follow-up drug regimens, and outcomes will be collected for up to 12 months [baseline (data from the previous year), 3, 6 and 12 months post-PGx intervention] for each patient to get a longitudinal perspective of implementing PGx into CDSS systems.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 30, 2023
Est. primary completion date January 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients meeting all the following criteria will be included: 1. Patient is enrolled in a healthcare organization where TRHC provides pharmacy services during the implementation period; 2. Patient is able to understand, and provide informed consent to participate. Exclusion Criteria: - Patients with one of the following criteria will be excluded: 1. Have taken an investigational product in the last 30 days; 2. Current use of illicit substances; 3. Any other medical, cognitive or physical abnormality, disease, or disorder that would prohibit the patient from completing study procedures in the judgement of the investigator and/or the prescriber.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pharmacogenomic Testing
Cheek swab as a part of routine care

Locations

Country Name City State
United States Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
Tabula Rasa HealthCare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure success of implementation of the PGx consultation process, including TRHC's CDSS (providing patient-specific PGx and phenotypic reviews) Quantitative 1 year
Primary Assess uptake of recommendations based on PGx is associated with improved outcomes in patients Quantitative 1 year
Secondary To determine usability of implementation of PGx consult during the process of medication review as measured by clinician response to survey. Qualitative / Quantitative 1 year
Secondary To determine the acceptability of recommendations provided on the basis of PGx information as measured by acceptance of the recommendation and changes in prescription made after information provided. Quantitative 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05531396 - Agility Training on Physical Performance, Cognitive Function and Brain Activities in Elderly N/A
Completed NCT03580447 - The Effect of Citrus Extract on Oxidative Stress N/A
Recruiting NCT04096547 - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Completed NCT03339791 - Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial N/A
Completed NCT03566719 - Effect of an Exercise Program on Risk of Fall in a Community Dwelling Older Adults N/A
Completed NCT02138968 - Clinical and Economic Assessment of a Pre-frail Screening Program N/A
Completed NCT01368029 - Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine Phase 1
Not yet recruiting NCT01182961 - The Use of Virtual Reality for the Gait Training of Elderly Fallers N/A
Completed NCT01899586 - Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly N/A
Completed NCT00961012 - The Big Squeeze (Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions) N/A
Completed NCT00748683 - Development of an Integrated Health Care Environment for Elderly With RFID Technology Phase 0
Completed NCT00533065 - Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone N/A
Completed NCT00798668 - The Body's Response to Food Intake in Trained, Older Adults N/A
Completed NCT00324701 - Telepsychology-Service Delivery for Depressed Elderly Veterans N/A
Completed NCT00217113 - An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly N/A
Completed NCT03666793 - Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care N/A
Recruiting NCT06030804 - Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery N/A
Recruiting NCT05014750 - Frailty of Elderly With Valvular Heart Disease and the Short Term Adverse Events
Completed NCT05021432 - Virtual Reality And Task Oriented Circuit Training Among Elderly Population N/A
Active, not recruiting NCT04132492 - AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients